#VisualAbstract: Ivermectin does not improve recovery time in adults with mild to moderate COVID-19 infection
Click here to read this study in JAMA.
Read MoreOct 27, 2022
Click here to read this study in JAMA.
Read MoreOct 27, 2022
1. In comparison to the best available medical care, a greater proportion of patients with...
Read MoreOct 27, 2022
Click here to read this study in NEJM.
Read MoreOct 25, 2022
Click to read this study in JAMA.
Read MoreOct 23, 2022
Click here to read this study in NEJM.
Read MoreOct 23, 2022
Click here to read this study in JAMA Psychiatry.
Read MoreOct 21, 2022
Click to read this study in JAMA Otolaryngology – Head & Neck Surgery.
Read MoreOct 21, 2022
1. Pembrolizumab-alone or pembrolizumab-chemotherapy prolonged overall survival vs...
Read MoreOct 21, 2022
Click to read this study in the Journal of Clinical Oncology.
Read MoreOct 21, 2022
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab...
Read MoreOct 15, 2022
Click to read this study in the Journal of Clinical Oncology.
Read MoreOct 15, 2022
1. In this randomized controlled trial, treatment of acute pyelonephritis and complicated urinary...
Read MoreOct 15, 2022
1. The composite of MRI-detected brain infarcts and symptomatic ischemic stroke was comparable...
Read MoreOct 11, 2022
1. Dapagliflozin was shown to reduce the risk of disease progression and cardiovascular death in...
Read MoreOct 11, 2022
Click to read this study in the Journal of Clinical Oncology.
Read MoreOct 11, 2022
1. In this randomized controlled trial, in participants with problem alcohol use, individuals in...
Read MoreOct 11, 2022
Click here to read this study in JAMA.
Read MoreOct 11, 2022
Click here to read this study in JAMA.
Read MoreSep 28, 2022
Click to read this study in Clinical Cancer Research.
Read MoreSep 28, 2022
1. Adjuvant pembrolizumab significantly improved disease-free survival in comparison to placebo in...
Read More